Ensysce Biosciences, Inc.: Series A $1.5M

Posted in I - Series A, Q - 2Q10, R - SOUTH WEST, X - Device (Delivery), XX - TX

Ensysce Biosciences (Houston, TX) a development-stage biopharma company focused on carbon nanotube complexes for chemotherapeutic transport, closed a $1.5M Series A financing. Participants include Texas Emerging Technology Fund.

Palmaz Scientific, Inc.: Series A $3M

Posted in I - Series A, Q - 2Q10, R - SOUTH WEST, X - Biomaterial, XX - TX

Palmaz Scientific (Dallas, TX) a development-stage nano-biomaterials company focused on a vapor deposition process to increase the reliability of implantable prosthetic devices, closed a $3M Series A financing. Participants include Texas Emerging Technology Fund.

Ortho Kinematics, Inc.: Series A $2.0M

Posted in I - Series A, Q - 4Q09, R - SOUTH WEST, X - Device (Diagnostic), X - Device (Spine), XX - TX

Ortho Kinematics (Austin, TX) a development-stage spine diagnostics company focused on inter-vertebral motion analysis, closed a $2M Series A financing. Participants include PTV Sciences, Texas Emerging Technology Fund and Gatebridge Investments.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Terapio Corp.: Series A $5M

Posted in I - Series A, Q - 4Q09, R - SOUTH WEST, X - Radiodermatitis, X - THx Delivery

Terapio (Austin, TX) a preclinical-stage biopharmaceutical company focused on radiodermatitis, closed a $5M Series A financing. Participants have included Santé Ventures and Texas Emerging Technology Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Bellicum Pharmaceuticals, Inc.: Series A $4.5M

Posted in I - Series A, Q - 4Q09, R - SOUTH WEST, X - Oncology, X - Vaccines

Bellicum Pharmaceuticals (Houston, TX) a clinical-stage biopharmaceutical company focused on immune-modulating therapeutic vaccines for prostate cancer, closed a $4.5M Series A financing. Particiapnts include the Texas Emerging Technology Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...